Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 19/20 | 0.62 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | S1PR3 | Q99500 | 7/20 | 0.56 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.49 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2121790 | 0.92 | S1PR1 (0.63) | S1PR1S1PR5CYP2C9KCNH2CYP3A4 | |
| SCHEMBL2121831 | 0.90 | S1PR1 (0.78) | S1PR1S1PR5CYP2C9KCNH2CYP3A4 | |
| SCHEMBL12852192 | 0.86 | S1PR1 (0.59) | S1PR1S1PR5CYP2C9KCNH2CYP3A4 | |
| SCHEMBL2121251 | 0.86 | S1PR1 (0.74) | S1PR1S1PR5CYP2C9KCNH2CYP3A4 | |
| SCHEMBL3062031 | 0.85 | S1PR1 (0.81) | S1PR1S1PR5CYP2C9KCNH2CYP3A4 | |
| SCHEMBL12852184 | 0.84 | S1PR1 (0.63) | S1PR1S1PR5CYP2C9KCNH2CYP3A4 | |
| SCHEMBL2125536 | 0.84 | S1PR1 (0.58) | S1PR1S1PR5CYP2C9KCNH2CYP3A4 | |
| SCHEMBL2602052 | 0.83 | S1PR1 (0.66) | S1PR1S1PR5CYP2C9KCNH2CYP3A4 | |
| SCHEMBL3062837 | 0.83 | S1PR1 (0.69) | S1PR1S1PR5CYP2C9KCNH2CYP3A4 | |
| SCHEMBL2134294 | 0.82 | S1PR1 (0.56) | S1PR1S1PR5CYP2C9KCNH2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8278324-B2 | Oxadiazole derivatives active on sphingosine-1-phosphate (S1P) | GLAXO GROUP LIMITED (GB) | 2012-10-02 | — | — | US | disclosed |
| US-20100273827-A1 | OXADIAZOLE DERIVATIVES ACTIVE ON SPHINGOSINE-1-PHOSPHATE (S1p) | GLAXO GROUP LIMITED (GB) | 2010-10-28 | — | — | US | disclosed |
| US-20100152235-A1 | OXADIAZOLE DERIVATIVES ACTIVE ON SPHINGOSINE-1-PHOSPHATE (S1P) | GLAXO GROUP LIMITED (GB) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152235-A1 | OXADIAZOLE DERIVATIVES ACTIVE ON SPHINGOSINE-1-PHOSPHATE (S1P) | S1PR3, S1PR1, S1PR2 | S1PR1 2/4885S1PR5 5/4885CYP2C9 3281/4885 |
| US-20100273827-A1 | OXADIAZOLE DERIVATIVES ACTIVE ON SPHINGOSINE-1-PHOSPHATE (S1p) | S1PR3, S1PR1, S1PR2 | S1PR1 2/4885S1PR5 5/4885CYP2C9 3248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.